Compare WFCF & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WFCF | CNTX |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.5M | 57.2M |
| IPO Year | 2006 | 2021 |
| Metric | WFCF | CNTX |
|---|---|---|
| Price | $12.50 | $0.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 4.3K | ★ 1.8M |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.39 |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $20,774,416.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $133.10 | ★ N/A |
| Revenue Growth | ★ 16.69 | N/A |
| 52 Week Low | $9.15 | $0.43 |
| 52 Week High | $22.15 | $3.62 |
| Indicator | WFCF | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.96 | 39.74 |
| Support Level | $12.01 | $0.43 |
| Resistance Level | $13.27 | $0.68 |
| Average True Range (ATR) | 0.63 | 0.04 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 25.21 | 30.28 |
Where Food Comes From Inc is a third-party food verification company conducting both on-site and desk audits to verify that claims being made about livestock, food, other high-value specialty crops and agricultural and aquaculture products are accurate. The company supports farmers, ranchers, vineyards, wineries, processors, retailers, distributors, trade associations, and restaurants with a wide variety of value-added services provided through its family of verifiers, including International Certification Services, Validus Verification Services, and others. It also provides a wide range of professional consulting services. It generates the majority of its revenue from Verification and certification services.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.